{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-268939","form_type":"8-K","ticker":"VOR","cik":"0001817229","company_name":"Vor Biopharma Inc.","filed_at":"2023-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.634621+00:00","generated_at":"2026-06-09T00:51:47.716117+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Vor Bio: ASH presentations show trem-cel engraftment; CD33CART 40% complete remission at highest dose","bullets":["VBP101 (trem-cel) abstract accepted for oral at ASH; shows robust neutrophil engraftment and hematologic protection from Mylotarg.","CD33CART Phase 1: 2/5 (40%) evaluable patients at DL4 achieved complete remission; 4/19 had CRS ≥ Grade 3.","VCAR33 ALLO uses same CAR-T construct as CD33CART but from healthy donors; VBP301 trial-in-progress poster at ASH.","Preclinical collaboration with Janssen: CD33-deleted allografts synergistic with JNJ-67571244, reducing cytokines.","Single-cell analysis of 28 AML patients (most comprehensive to date) accepted for oral presentation at ASH."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-268939","json":"https://secwatch.observer/filing/0001193125-23-268939.json","markdown":"https://secwatch.observer/filing/0001193125-23-268939.md","text":"https://secwatch.observer/filing/0001193125-23-268939.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1817229/000119312523268939/0001193125-23-268939-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1817229/000119312523268939/d554165d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T00:51:47.716117+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}